Clinical experience with Zarzio® in Europe: What have we learned?

Supportive Care in Cancer

Volumn 21, Issue 10, 2013, Pages 2925-2932

  Gascón, Pere ^a   Tesch, Hans ^b   Verpoort, Karl ^c   Rosati, Maria Sofia ^d   Salesi, Nello ^e   Agrawal, Samir ^f   Wilking, Nils ^g   Barker, Helen ^h   Muenzberg, Michael ⁱ   Turner, Matthew ⁱ  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Bethanien Krankenhaus Frankfurt   (Germany)

^c Universitatskrankenhaus Eppendorf   (Germany)

^d POLICLINICO UMBERTO I   (Italy)

^e Ospedale di Gaeta M di Liegro   (Italy)

^f ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^g KAROLINSKA INSTITUTE   (Sweden)

^h Rotherham NHS Foundation Trust   (United Kingdom)

ⁱ Sandoz Pharma Ltd   (Switzerland)

Author keywords

Biosimilar; Chemotherapy induced neutropenia; Cost effectiveness; Filgrastim; G CSF

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; XM 02;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BIOEQUIVALENCE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CD34 SELECTION; CLINICAL PRACTICE; COLORECTAL CANCER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG QUALITY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; EUROPE; FEBRILE NEUTROPENIA; HEALTH CARE ACCESS; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; LEUKEMIA; LUNG CANCER; LYMPHOMA; MULTIPLE MYELOMA; NEUTROPENIA; OVARY CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SOLID TUMOR; STEM CELL MOBILIZATION;

BIOSIMILAR PHARMACEUTICALS; COST-BENEFIT ANALYSIS; EUROPE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASMS; NEUTROPENIA;

EID: 84884283941     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1911-7     Document Type: Review

References (46)

1. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: nonclinical and clinical issues. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor [EMEA/CHMP/BMWP/31329/2005]. European Medicines Agency, London, 2006. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003955.pdf [Accessed 24 August 2012]
2. European Union. Commission Directive 2003/63/EC, amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do?uri=OJ:L:2003:159:0046:0094:EN:PDF [Accessed 24 August 2012]
3. European Union. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code relating to medicinal products for human use. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri= CONSLEG:2001L0083:20091005:EN:PDF [Accessed 24 August 2012]
4. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf [Accessed 24 August 2012]
5. Gascón P (2012) Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol 7(suppl 1):S29-S34
6. Aapro MS, Bohlius J, Cameron DA et al (2011) Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8-32
7. Genazzani AA, Biggio G, Caputi AP et al (2007) Biosimilar drugs: concerns and opportunities. BioDrugs 21:351-356
8. Mellstedt H (2010) Implications of the development of biosimilars for cancer treatment. Future Oncol 6:1065-1067
9. Mellstedt H, Niederwieser D, Ludwig H (2008) The challenge of biosimilars. Ann Oncol 19:411-419
10. Niederwieser D, Schmitz S (2011) Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol 86:277-288
11. Zelenetz AD, Ahmed I, Braud EL, et al. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw 2011; Suppl 4: S1-S22
12. Schellekens H, Moors E (2010) Clinical comparability and European biosimilar regulations. Nat Biotechnol 28:28-31
13. Sörgel F, Lerch H, Lauber T (2010) Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs 24:347-357
14. Skrlin A, Radic I, Vuletic M, Schwinke D, Runac D, Kusalic T, Paskvan I, Krsic M, Bratos M, Marinc S (2010) Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals 38:557-566
15. Gascón P, Fuhr U, Sörgel F et al (2010) Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol 21:1419-1429
16. Green MD, Koelbl H, Baselga J et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29-35
17. Holmes FA, O'Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-731
18. Lubenau H, Bias P, Maly AK, Siegler KE, Mehltretter K (2009) Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 23:43-51
19. Lubenau H, Sveikata A, Gumbrevicius G, Macijauskiene J, Fokas V, Kazlauskas S, Janulionis V (2009) Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther 47:275-282
20. del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H (2008) XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 8:332
21. Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, Del Giglio A (2009) XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 4:736-740
22. Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A (2009) XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 50:374-379
23. Waller CF, Bronchud M, Mair S, Challand R (2010) Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 89:971-978
24. Waller CF, Bronchud M, Mair S, Challand R (2010) Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 89:927-933
25. Waller CF, Semiglazov VF, Tjulandin S, Bentsion D, Chan S, Challand R (2010) A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 33:504-511
26. Gascón P, Aapro M, Ludwig H et al (2011) Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Crit Rev Oncol Hematol 77:184-197
27. Tesch H, Indorf M, Schaller-Kranz T. Supportive treatment of chemotherapy-induced neutropenia with biosimilar filgrastim: the HEXAFIL non-interventional study. European Multidisciplinary Cancer Congress (EMCC) 2011; Abstract Book 280: A4025. Available online at: http://www.ecco-org.eu/ ecco-content/ECCO16-AbstractBook/files/assets/seo/page308.html [Accessed 24 August 2012]
28. Verpoort K, Möhler TM. A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre. Ther Adv Med Oncol 2012, doi: 10.1177/1758834012461330
29. Salesi N, Di Cocco B, Colonna M, Veltri E (2012) Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF. Future Oncol 8:625-630
30. Rosati MS, Baciarello G, Di Seri M, Basile ML, Lo Russo V, Frati L (2011) Biosimilar filgrastim in routine clinical practice: a single centre experience. J Geriatr Oncol 2(Suppl 1):S54, P79
31. Morrison VA, Wong M, Hershman D et al (2007) Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 13:337-348
32. Skarlos DV, Timotheadou E, Galani E et al (2009) Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. Oncology 77:107-112
33. Lefrère F, Brignier AC, Elie C et al (2011) First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. Adv Ther 28:304-310
34. Ianotto JC, Tempescul A, Yan X et al (2012) Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients. Bone Marrow Transplant 47:874-876
35. Dmoszynska A, Manko J, Croneck AW et al (2012) Comparable efficacy and safety of biosimilar and originator G-CSF in patients undergoing haematopoietic stem cell mobilisation. Bone Marrow Transplant 47(suppl. 1):S243, P700
36. Yafour N, Osmani S, Talhi S et al (2012) Biosimilar G-CSF (filgrastim) is also efficient for peripheral blood stem cell mobilisation and no cryopreserved autologous transplantation. Bone Marrow Transplant 47(Suppl 1):S243, P725
37. Czerw T, Kruzel T, Sadus-Wojciechowska M et al (2012) Comparison of two formulations of filgrastim, Neupogen (Amgen) and Zarzio (Sandoz), used to accelerate neutrophil recovery after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 47(suppl 1):S316, P872
38. Kotwica K, Cioch M, Wach M et al (2012) Biosimilar G-CSF is effective in reducing the duration of neutropenia after autologous bone marrow transplantation. Bone Marrow Transplant 47(Suppl 1):S316, P873)
39. Shaw BE, Confer DL, Hwang WY, Pamphilon DH, Pulsipher MA (2011) Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica 96:942-7
40. Azar N, Choquet S, Garnier A et al (2012) Use of a biosimilar G-CSF in allogeneic stem cell mobilisation. Bone Marrow Transplant 47(suppl 1):S316, P727
41. Schmitt M, Lena D, Schneider, et al. Use of the G-CSF biosimilar Ratiograstim® to mobilize peripheral stem cells in healthy donors for allogeneic stem cell transplantation. Abstract presented at the 53rd annual meeting of the American Society of Hematology, December 10-13, 2011, San Diego, CA, USA. Available online at: https://ash.confex.com/ash/2011/webprogram/ Paper38776.html [Accessed 24 August 20120]
42. Becker P, Brauninger S, Bialleck H et al (2013) Biosimilar filgrastim mobilizes haematopoietic stem cells in healthy volunteer donors with expected efficiency and typical acute adverse effects: interim results of a post-authorization safety study. Bone Marrow Transplant 48(suppl 2s):O177
43. Cornes P (2012) The economic pressures for biosimilar drug use in cancer medicine. Target Oncol 7(suppl 1):S57-S67
44. Aapro M, Cornes P, Abraham I (2012) Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract 18:171-179
45. IMS Health. MIDAS Global Biologics database, 2012. www.imshealth.com
46. Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012 Oct 23. doi: 10.1182/blood-2012-04-425744